Published in Transl Psychiatry on January 13, 2015
Plasma phospholipids and prevalence of mild cognitive impairment and/or dementia in the ARIC Neurocognitive Study (ARIC-NCS). Alzheimers Dement (Amst) (2016) 0.86
Lipidomics: Techniques, Applications, and Outcomes Related to Biomedical Sciences. Trends Biochem Sci (2016) 0.82
The ratio of phosphatidylcholines to lysophosphatidylcholines in plasma differentiates healthy controls from patients with Alzheimer's disease and mild cognitive impairment. Alzheimers Dement (Amst) (2015) 0.82
Plasma 24-metabolite Panel Predicts Preclinical Transition to Clinical Stages of Alzheimer's Disease. Front Neurol (2015) 0.79
Lipidomics comparing DCD and DBD liver allografts uncovers lysophospholipids elevated in recipients undergoing early allograft dysfunction. Sci Rep (2015) 0.77
Non-alcoholic fatty liver disease induces signs of Alzheimer's disease (AD) in wild-type mice and accelerates pathological signs of AD in an AD model. J Neuroinflammation (2016) 0.77
Blood metabolite markers of neocortical amyloid-β burden: discovery and enrichment using candidate proteins. Transl Psychiatry (2016) 0.77
Metabolomic method: UPLC-q-ToF polar and non-polar metabolites in the healthy rat cerebellum using an in-vial dual extraction. PLoS One (2015) 0.76
The Impact of Ischemia/Reperfusion Injury on Liver Allografts from Deceased after Cardiac Death versus Deceased after Brain Death Donors. PLoS One (2016) 0.76
Expanding the Repertoire of Biomarkers for Alzheimer's Disease: Targeted and Non-targeted Approaches. Front Neurol (2015) 0.76
Neuronal human BACE1 knockin induces systemic diabetes in mice. Diabetologia (2016) 0.75
Prospective associations of plasma phospholipids and mild cognitive impairment/dementia among African Americans in the ARIC Neurocognitive Study. Alzheimers Dement (Amst) (2016) 0.75
Metabolomic Profiling of Bile Acids in Clinical and Experimental Samples of Alzheimer's Disease. Metabolites (2017) 0.75
Global prevalence of dementia: a Delphi consensus study. Lancet (2005) 23.30
Adjusting batch effects in microarray expression data using empirical Bayes methods. Biostatistics (2006) 22.61
Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nat Genet (2009) 15.15
Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease. Nat Genet (2009) 14.86
Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease. Nat Genet (2013) 9.46
Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. Nat Genet (2011) 9.23
Human metabolic individuality in biomedical and pharmaceutical research. Nature (2011) 6.56
Plasma phospholipids identify antecedent memory impairment in older adults. Nat Med (2014) 3.45
Cholesteryl ester transfer protein: a novel target for raising HDL and inhibiting atherosclerosis. Arterioscler Thromb Vasc Biol (2003) 3.26
Metabolic footprint of diabetes: a multiplatform metabolomics study in an epidemiological setting. PLoS One (2010) 2.84
Metabolomics in early Alzheimer's disease: identification of altered plasma sphingolipidome using shotgun lipidomics. PLoS One (2011) 2.30
Microvascular injury and blood-brain barrier leakage in Alzheimer's disease. Neurobiol Aging (2006) 2.03
Metabonomics in pharmaceutical R&D. FEBS J (2007) 1.93
Alzheimer disease: epidemiology, diagnostic criteria, risk factors and biomarkers. Biochem Pharmacol (2014) 1.86
Age-dependent neurodegeneration and Alzheimer-amyloid plaque formation in transgenic Drosophila. J Neurosci (2004) 1.74
The ACAT inhibitor CP-113,818 markedly reduces amyloid pathology in a mouse model of Alzheimer's disease. Neuron (2004) 1.71
Lipids of human meibum: mass-spectrometric analysis and structural elucidation. J Lipid Res (2007) 1.64
Comparative lipidomic analysis of mouse and human brain with Alzheimer disease. J Biol Chem (2011) 1.51
Metabolome in progression to Alzheimer's disease. Transl Psychiatry (2011) 1.33
The role of seladin-1/DHCR24 in cholesterol biosynthesis, APP processing and Abeta generation in vivo. EMBO J (2006) 1.29
Identification of a new plasma biomarker of Alzheimer's disease using metabolomics technology. J Lipid Res (2011) 1.24
ACAT1 gene ablation increases 24(S)-hydroxycholesterol content in the brain and ameliorates amyloid pathology in mice with AD. Proc Natl Acad Sci U S A (2010) 1.23
Fatty acid composition of cholesteryl esters of human meibomian gland secretions. Steroids (2010) 1.19
Biomarkers for disease modification trials--the innovative medicines initiative and AddNeuroMed. J Nutr Health Aging (2007) 1.12
Evidence of altered phosphatidylcholine metabolism in Alzheimer's disease. Neurobiol Aging (2013) 1.12
Mitochondrial dysfunction and immune activation are detectable in early Alzheimer's disease blood. J Alzheimers Dis (2012) 1.11
Cholesteryl ester transfer protein inhibition to reduce cardiovascular risk: Where are we now? Trends Pharmacol Sci (2011) 0.97
A proposed metabolic strategy for monitoring disease progression in Alzheimer's disease. Electrophoresis (2009) 0.96
Acat1 knockdown gene therapy decreases amyloid-β in a mouse model of Alzheimer's disease. Mol Ther (2013) 0.92
In-vial dual extraction for direct LC-MS analysis of plasma for comprehensive and highly reproducible metabolic fingerprinting. Anal Chem (2012) 0.91
Elevated stearoyl-CoA desaturase in brains of patients with Alzheimer's disease. PLoS One (2011) 0.90
Alzheimer's disease beyond the genomic era: nuclear magnetic resonance (NMR) spectroscopy-based metabolomics. J Cell Mol Med (2008) 0.90
Mass and relative elution time profiling: two-dimensional analysis of sphingolipids in Alzheimer's disease brains. Biochem J (2011) 0.86
Dyslipidemia and the risk of Alzheimer's disease. Curr Atheroscler Rep (2013) 0.85
Alzheimer's disease: brain desmosterol levels. J Alzheimers Dis (2013) 0.82
Current strategies in the discovery of small-molecule biomarkers for Alzheimer's disease. Bioanalysis (2011) 0.77